Trevena reports completion of TRV027 Phase 2a study in advanced heart failure ... News-Medical.net Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, today announced that it has successfully completed a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced heart ... |
